|
1
|
Ginsberg RJ, Kris MK and Armstrong JG:
Cancer of the lung. Cancer: Principles and Practice of Oncology.
DeVita VT, Hellman S and Rosenberg SA: 4th edition. Lippincott,
Williams and Wilkins; Philadelphia: pp. 673–682. 1993
|
|
2
|
Sakata R, Fujii Y and Kuwano H: Thoracic
and cardiovascular surgery in Japan during 2009. Annual report by
the Japanese Association for Thoracic Surgery Gen Thorac Cardiovasc
Surg. 59:636–667. 2011.
|
|
3
|
Postus PE: Chemotherapy for non-small cell
lung cancer: the experience of the lung cancer cooperative group of
the European Organization for Research and Treatment of Cancer.
Chest. 113(Suppl 1): S28–S31. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kensler TW and Wakabayashi N: Nrf2: friend
or foe for chemoprevention? Carcinogenesis. 31:90–99. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moi P, Chank K, Asunis I, et al: Isolation
of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper
transcriptional activator that binds to the tandem NF-E2/AP1 repeat
of the beta-globin locus control region. Proc Natl Acad Sci USA.
91:9926–9930. 1994. View Article : Google Scholar
|
|
6
|
Solis LM, Behrens C, Dong W, et al: Nrf2
and Keap1 abnormalities in non-small cell lung carcinoma and
association with clinicopathologic features. Clin Cancer Res.
16:3743–3753. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sasaki H, Hikosaka Y, Okuda K, et al:
NFE2L2 gene mutation in male Japanese squamous cell carcinoma of
the lung. J Thorac Oncol. 5:786–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shibata T, Ohta T, Tong KI, et al: Cancer
related mutations in Nrf2 impair its recognition by Keap1-Cul3 E3
ligase and promote malignancy. Proc Natl Acad Sci USA.
105:13568–13573. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hu Y, Ju Y, Lin D, et al: Mutation of the
Nrf2 gene in non-small cell lung cancer. Mol Biol Rep.
39:4743–4747. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Young LC, Campling BG, Voskoglou-Nomikos
T, et al: Expression of multidrug resistance protein-related genes
in lung cancer: correlation with drug response. Clin Cancer Res.
5:673–680. 1999.PubMed/NCBI
|
|
11
|
Kool M, van der Linden M, de Haas M, et
al: MRP3, an organic anion transporter able to transport
anti-cancer drugs. Proc Natl Acad Sci USA. 96:6914–6919. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lockhart AC, Tirona RG and Kim RB:
Pharmacogenetics of ATP-binding cassette transporters in cancer and
chemotherapy. Mol Cancer Ther. 2:685–698. 2003.PubMed/NCBI
|
|
13
|
Mahaffey CM, Zhang H, Rinna A, et al:
Multidrug resistant protein-3 gene regulation by the transcription
factor Nrf2 in human bronchial epithelial and non-small cell lung
carcinoma. Free Radic Biol Med. 46:1650–1657. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Merikallio H, Pääkkö P, Kinnula VL, et al:
Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are
prognostic factors in lung cancer. Hum Pathol. 43:577–584. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang H, Wang W, Zhang Y, et al: The role
of NF-E2-related factor 2 in predicting chemoresistance and
prognosis in advanced non-small cell lung carcinomas. Clin Lung
Cancer. 12:166–171. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mahaffey CM, Mahaffey NC, Holland W, et
al: Aberrant regulation of the MRP3 gene in non-small cell lung
carcinoma. J Thorac Oncol. 7:34–39. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mahaffey CM, Zhang H, Rinna A, et al:
Multidrug resistant protein-three gene regulation by the
transcription factor Nrf2 in human bronchial epithelial and
non-small cell lung carcinoma. Free Radiac Biol Med. 46:1650–1657.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Itoh K, Chiba T, Takahashi S, et al: An
Nef2/small Maf heterodimer mediates the induction of phase II
detoxifying enzyme genes through antioxidant response elements.
Biochem Biophys Res Commun. 236:313–322. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rushmore TH and Kong AN: Pharmacogenomics,
regulation and signaling pathways of phase I and II drug
metabolizing enzymes. Curr Drug Metab. 3:481–490. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ngyyen T, Yang CS and Pickett CB: The
pathways and molecular mechanisms regulating Nrf2 activation in
response to chemical stress. Free Radic Biol Med. 37:433–441. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Singh A, Boldin-Adamsky S, Thimmulappa RK,
et al: RNAi-mediated silencing of nuclear factor
erythroid-2-related factor 2 gene expression in non-small cell lung
cancer inhibits tumor growth and increases efficacy of
chemotherapy. Cancer Res. 68:7975–7984. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Arisawa T, Tahara T, Shibata T, et al:
Nrf2 gene promoter polymorphism and gastric carcinogenesis.
Hepatogastroenterology. 55:750–754. 2008.PubMed/NCBI
|
|
19
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar
|
|
20
|
Zhou J, Schmid T, Schnitzer S and Brüne B:
Tumor hypoxia and cancer progression. Cancer Lett. 237:10–21. 2006.
View Article : Google Scholar
|
|
21
|
Homma S, Ishii Y, Morishima Y, et al: Nrf2
enhances cell proliferation and resistance to anticancer drugs in
human lung cancer. Clin Cancer Res. 15:3423–3432. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cho JM, Manandhar S, Lee HR, et al: Role
of Nrf2-antioxidant system in cytotoxicity mediated by anticancer
cisplatin: implication to cancer cell resistance. Cancer Lett.
260:96–108. 2008. View Article : Google Scholar : PubMed/NCBI
|
